期刊文献+

肿瘤标志物的联合检测在肺癌诊断中的临床价值

Diagnostic value of combined detection of serum tumor markers in patients with lung cancer
原文传递
导出
摘要 目的探讨血清中CEA、CA125、NSE和CYFRA21-1四种肿瘤标志物联合检测在不同组织类型肺癌中的临床诊断价值。方法采用电化学发光免疫分析技术测定116例肺癌患者及65例健康人血清中的CEA、CA125、NSE利CYFRA21-1水平。结果CYFRA21-1、NSE、CEA、CA125四项肿瘤标志物肺癌组检测水平均显著高于对照组(P〈0.01),肿瘤标志物测定水平与病理组织类型有关。其中CYFRA21-1在鳞癌及腺癌的阳性率分别为73.21%、63.64%;NSE在小细胞肺癌的阳性率为62.50%;CEA和CA125检测的阳性率及血清水平以腺癌最高;四项联合检测的阳性率为82.76%。结论血清CEA、CA125、NSE和CYFRA21-1的联合检测有助于提高肺癌的诊断效率,并对组织分型有较高的参考价值。 Objective To investigate the clinical value of combined measurement of serum CEA, CA125, NSE, CY- FRA21-1 for the diagnosis of lung cancer. Methods One hundred and sixteen patients with lung cancer confirmed histologically were studied. The levels of CEA, CA125 CYFRA21-1, NSE were assayed and compared between the lung cancer group( 116 cases) and healthy control group(65 cases) by electrochemiluminesence immunoassay. Results The levels of CYFRA21-1, NSE,CEA, and CA125 in the lung cancer group were significantly higher than those in the control group(P〈0.01). The levels of serum CEA,CA125, CYFRA 21-1 and NSE were related to types of pa- thology. The highest positive rates of CYFRA 21-1 for squamous cell carcinoma were 73.21% and 63.64% for ade- nocarcinoma;Tbe positivity of NSE for small cell lung cancer (SCLC) was 62.50% ;The higher levels and positivity of CEA and CA125 appeared in adenocareinoma. Their combined detection could markedly improve the positivity for lung cancer detection (82.76%). Conclusion CEA,CA125 ,CYFRA21-1 and NSE are useful for the diagnosis of the lung cancer and histological type, especially combining detection of the four serum tumor markers .
出处 《中国误诊学杂志》 CAS 2012年第18期4869-4871,共3页 Chinese Journal of Misdiagnostics
关键词 肺肿瘤/代谢 癌胚抗原/血液 CA-125抗原/血液 磷酸丙酮酸水合酶/血液 抗原 肿瘤/血液 角蛋白质类/血液 Lung Neoplasms/metabolism Carcinoembryonic Antigen/Blood CA-125 Antigen/Blood Phosphopyruvate Hydratase/Blood Antigens, Neoplasm/Blood Keratins/Blood
  • 相关文献

参考文献10

  • 1Sawabata N,Ohta M, Takeda S, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer[J]. Ann Thorac Surg, 2002, 74(1):174-179.
  • 2Molina R, Eilella X, Auge JM, et al. Tumormarkers (CEA, CA125,CYFRA 2121, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors[J]. Tumour Biol, 2003, 24(4) :209-218.
  • 3Pollan M, Varela G, Tomes A, et al. Clinical value of p53, cerbB22, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer[J]. Int J Cancer, 2003, 107(5) :781-790.
  • 4Plavec G, Ninkovic'M, Kozlovacki G, et al. Tumormarkers in pleural effusions in bronchogenic carcinoma and tuberculosis[J]. Vojnosanit Pregl, 2002, 59 (1): 23-28.
  • 5Salgia R, Harpole D, Harndon JE, et al. Role of serum tumor markers CA125 and CEA in non-small cell lung cancer[J]. Anticancer Res, 2001,21(2B):1241-1246.
  • 6Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patient swith lung cancer[J]. Respiration,2002, 69(1):25-29.
  • 7Gu CD, Osaki T, Oyama T, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patientswith completely resected non-small cell lung cancerz impact on recurrence and Survival [J]. Ann Surg, 2002, 235(1):133-139.
  • 8Elbert W,Muley T, Trainer C, et al. Comparison of changes in the NSE levels with clinical assessment in the therapymonitoring of patients with SCLC[J]. Anticancer Res, 2002, 2?. (2B): 1083.
  • 9宋丽华,宋现让,张锡芹,齐洁琳,李秀菊,田禾,步兵.小细胞肺癌患者预后因素分析[J].中华肿瘤杂志,2004,26(7):413-416. 被引量:23
  • 10张昕,张湘茹.肺癌肿瘤标志物的临床价值[J].癌症进展,2005,3(2):159-162. 被引量:42

二级参考文献24

  • 1[1]Ando S, Kimura H, Iwai N, et al. Optimal combination of seven tumor markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Research, 2001, 21 (4) :3085
  • 2[2]Niklinski J, Furman M, Burzyowski T. Preoperative CYFRA21-1 level as aprognostic in resected primary squamous cell lung cancer. B J Cancer, 1996, 74:956
  • 3[3]Antonio LP, Antonio JT, Marisa M. Quantitative analysis of CEA, SCC, CA125, and CA50 cytosolic content in NSCLC.Cancer, 1996, 73 (9) :2305
  • 4[4]Jan K, Ewa W, Andrzej R. C RA21-1, TPA, TPS, SCC and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Research,2000, 20:5035
  • 5[5]J Watine. Prognostic evaluation of primarynon-small cell lung carcinoma patients usingbiological fluid varibles. Scand J Clin Lab Invest, 2000, 60:259
  • 6[6]Kulpa J, Wojcik E, Reinfuss M. Carcinoembryonic antigen,squamous cell carcinoma antigen, CYFRA 21-1, and neuronspecific enolase in squamous cell lung cancer patients. Clinical Chemistry, 2002, 48 (11) :1931
  • 7[7]DiezM, CerdanFJ, Ortega MD. Evaluation ofserum CA125 as a tumor markerin NSCLC. Cancer, 1991, 67:150
  • 8[8]Jan K, Ewa W, Marian R, et al. CEA, SCC, CYFRA21-1 and NSE in squamous cell lungcancer patients. Clinical Chemistry, 2002, 48 (11) :1931
  • 9[9]Alatas F, Alatas O, Metintas M. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay inpleural effusions. Lung cancer, 2001, 31 (1) :9
  • 10[10]Dize M, Torres A, Pollan M. Prognostic significance of serum CA125 assay inpatients with NSCLC. Cancer, 1994, 73 (5): 1368

共引文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部